InMed Pharmaceuticals Inc. has entered into a merger agreement with Mentari Therapeutics, Inc., with InMed as the acquiring parent company, effective May 19, 2026. The transaction involves two merger subsidiaries and includes contingent consideration mechanisms tied to net cash and company valuation.